The design of venous thromboembolism prophylaxis trials: Is enoxaparin more effective than fondaparinux?

International Journal of Clinical Practice

Volumn 57, Issue 4, 2003, Pages 289-294

  Lalourcey, Laurent ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; FONDAPARINUX; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL DESIGN; HUMAN; INCIDENCE; LOW DRUG DOSE; META ANALYSIS; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; REVIEW; SURGICAL PATIENT; SYMPTOMATOLOGY; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTICOAGULANTS; CLINICAL TRIALS; DOUBLE-BLIND METHOD; ENOXAPARIN; HUMANS; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0037527557     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Nicolaides AN, Bergqvist D, Hull R et al. Prevention of venous thromboembolism. Consensus statement. Int Angiol 1997; 16: 3-38.
2. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Sixth ACCP consensus conference on antithrombotic therapy. Chest 2001; 119: 132S-175S.
3. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358: 9-15.
4. Leclerc JR, Gent M, Hirsh J et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 1998; 158: 873-878.
5. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999; 81: 932-940.
6. Heit JA, Elliott CG, Trowbridge AA et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132: 853-861.
7. Bick RL, Haas SK. International consensus recommendations. Summary statement and additional suggested guidelines. Med Clin North Am 1998; 82: 613-633.
8. Colwell CW Jr. Low molecular weight heparin prophylaxis in total knee arthroplasty: the answer. Clin Orthop 2001; 392: 245-248.
9. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001; 21: 218-234.
10. Ornstein DL, Hong-Dice YG, Papini JR. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism. Mil Med 2001; 166: 593-601.
11. Prandoni P. Heparins and venous thromboembolism: current practice and future directions. Thromb Haemost 2001; 86: 488-498.
12. Keam SJ, Goa KL. Fondaparinux sodium. Drugs 2002; 62: 1673-1685.
13. Rosenberg RD. Biochemistry and pharmacology of low molecular weight heparin. Semin Hematol 1997; 34(4 suppl 4): 2-8.
14. Noble S, Peters DH, Goa KL. Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995; 49: 388-410.
15. Bara L, Bloch MF, Zitoun D, et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-452.
16. Hoppensteadt DA, Jeske W, Fareed J, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinol 1995; 6(suppl 1): S57-S64.
17. Gori AM, Fedi S, Pepe G, et al. Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration. Br J Haematol 2002; 117: 693-698.
18. Jeske W, Hoppensteadt D, Klauser R, et al. Effect of repeated aprosulate and enoxaparin administration on tissue factor pathway inhibitor antigen levels. Blood Coagul Fibrinol 1995; 6: 119-124.
19. Hansen JB, Sandset PM, Huseby KR, et al. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol 1998; 101: 638-646.
20. Andrassy K. Low molecular weight heparin and haemodialysis: neutralization by protamine chloride. Blood Coagul Fibrinol 1993; 4(suppl 1): S39-S43.
21. Turpie AGG, Gallus AS, Hoek JA, for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-625.
22. Walenga JM, Jeske WP, Samama MM et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 2002; 11: 397-407.
23. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG, for the steering committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-1310.
24. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG, for the steering committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-1304.
25. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG, for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) steering committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-1720.
26. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the PENTATHLON 2000 Study steering committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-1726.
27. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of four randomized double-blind studies. Arch Intern Med 2002; 162: 1833-1840.
28. Dahl OE, Bergqvist D. Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery. Curr Opin Pulm Med 2002; 8: 394-397.
29. Dahl OE, Pedersen T, Kierulf P et al. Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery. Thromb Res 1993; 70: 451-458.
30. Dahl OE, Aspelin T, Lyberg T. The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs. Blood Coagul Fibrinol 1995; 6(8): 709-717.
31. Hull RD, Pineo GF, Stein PD et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 2001; 161: 1952-1960.
32. Heit JA. Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement. Thromb Res 2001; 101: V163-V173.
33. Rossi R, Agnelli G. Current role of venography in the diagnosis of deep-vein thrombosis. Minerva Cardioangiol 1998; 46: 507-514.
34. Lee AY, Hirsh J. Diagnosis and treatment of venous thromboembolism. Ann Rev Med 2002; 53: 15-33.
35. Keaton C. Noninvasive diagnosis of deep vein thrombosis in postoperative patients. Semin Thromb Hemost 2001; 27: 3-8.
36. Douketis JD, Eikelboom JW, Quinlan DJ, et al. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002; 162: 1465-1471.
37. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988; 208: 227-240.
38. Palmer AJ, Koppenhagen K, Kirchhof B et al. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised. clinical trials. Haemostasis 1997; 27: 75-84.
39. Robinson KS, Anderson DR, Gross M et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study: a randomized, controlled trial. Ann Intern Med 1997; 127: 439-445.
40. Sonaglia F, Rossi R, Agnelli G. End points in studies on the prevention of deep vein thrombosis. Semin Thromb Hemost 2001; 27: 41-46.
41. Davidson BL. What are the most reliable detection methods for deep vein thrombosis and pulmonary embolism to be used as endpoints in trials of venous thromboprophylaxis? Haemostasis 1998; 28(suppl 3): 113-119.
42. Prentice CRM. Are symptomatic endpoints acceptable in venous thromboprophylactic studies? Haemostasis 1998; 28(suppl 3): 109-112.
43. Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products for prophylaxis of intra- and post-operative venous thromboembolic risk. Available from: http//www.emea.eu.int/pdfs/human/ewp//070798en.pdf. Site accessed 22 November, 2002.
44. Food and Drug Administration/Center for Drug Evaluation and Research. Arixtra (fondaparinux sodium) injection. Available from: http//www.fda.gov/cder/foi/nda/2001/21-345_Arixtra.htm. Site accessed 22 November 2002.
45. European Agency for the Evaluation of Medicinal Products. European Public Assessment Report: Arixtra. Available from: http//www.eudra.org/humandocs/Humans/Epar/arixtra/arixtra.htm. Site accessed 22 November, 2002.